Novo Nordisk Juggles Pipeline Wins and Core Business Headwinds

Novo Nordisk advances rare heart disease drug Coramitug with FDA Fast Track, reports positive oral semaglutide data in teens, and builds an AI-driven pipeline amid a 35% stock dip.

The Danish pharmaceutical heavyweight has been navigating a turbulent stretch, with its stock down roughly 35 percent from a year ago. Yet behind the share-price weakness, Novo Nordisk is quietly assembling a multi-pronged strategy that spans rare cardiac diseases, adolescent diabetes, and artificial intelligence-driven drug discovery. Recent regulatory and clinical milestones suggest the company is racing to diversify beyond its flagship GLP-1 franchise before competitive pressures intensify.

FDA Fast Track for a Rare Heart Disease Drug

The US Food and Drug Administration has granted Fast Track designation to Coramitug, Novo Nordisk’s experimental antibody for ATTR amyloidosis with cardiomyopathy (ATTR-CM). This rare, life-threatening condition involves amyloid deposits accumulating in heart tissue. Coramitug is designed to clear existing amyloid while preventing further buildup, and Novo Nordisk internally views it as a potential best-in-class candidate within its drug class.

Fast Track status does not guarantee approval, but it facilitates more frequent communication with the regulator and can accelerate the review process. The designation is reserved for therapies addressing unmet medical needs — a criterion ATTR-CM clearly meets. Phase 2 data have already shown encouraging improvements in the cardiac biomarker NT-proBNP and several echocardiographic parameters, with more than 80 percent of trial participants already receiving standard therapy.

The pivotal Phase 3 trial, dubbed CLEOPATTRA, is now enrolling approximately 1,280 patients, with top-line results expected in 2029. Interim data could emerge sooner, potentially offering an earlier read on the drug’s prospects. Coramitug originated from Novo Nordisk’s 2021 acquisition of Prothena’s ATTR amyloidosis pipeline, a deal that includes milestone payments of up to $1.2 billion. So far, $150 million has been paid to Prothena.

Oral Semaglutide Scores in Teenagers

On a separate front, Novo Nordisk reported positive results from the PIONEER TEENS study, testing oral semaglutide in adolescents with type 2 diabetes. After 26 weeks, blood sugar levels dropped by 0.83 percent compared with placebo. The data are significant because existing treatments for this age group often fall short: metformin loses effectiveness in roughly half of young patients, while insulin carries risks of hypoglycemia and unwanted weight gain.

The company plans to file for regulatory approval in the US and Europe during the second half of 2026. If cleared, oral semaglutide would become the first GLP-1 pill approved for minors, giving Novo Nordisk a clear edge over US rival Eli Lilly, which has no presence in this pediatric segment. The addressable market is expanding rapidly, with forecasts projecting nearly 21 million affected adolescents globally by 2030.

Diversification Becomes a Necessity

These pipeline advances are not happening in isolation. Novo Nordisk also recently posted positive Phase 3 data for Etavopivat in sickle cell disease, underscoring a broader push into rare diseases and cardiology. The strategic pivot is driven by mounting pressure on the company’s core GLP-1 business. Management expects GLP-1 segment revenue to decline by 5 to 13 percent in 2026, squeezed by US Medicaid cuts, new pricing agreements, and intensifying competition.

The stock has shown signs of recovery in recent weeks, climbing roughly 15 percent over the past 30 days to trade at €35.62. That still leaves it about 35 percent below its level a year ago, reflecting persistent concerns about the core business. The secondary article notes a similar 14 percent short-term rebound, with the share price at €35.27.

AI Partnership and Long-Term Ambitions

Beyond near-term clinical milestones, Novo Nordisk is investing in next-generation drug development tools. A new partnership with OpenAI aims to leverage artificial intelligence to accelerate the discovery and design of new medicines. While details remain sparse, the collaboration signals the company’s intent to stay at the forefront of pharmaceutical innovation as it navigates a challenging transition period.

For now, investors are watching two key timelines: the CLEOPATTRA results in 2029 (or any interim data before then) and the regulatory filing for oral semaglutide in adolescents in the second half of 2026. Both represent potential catalysts that could help offset the headwinds facing Novo Nordisk’s core GLP-1 franchise — but neither will arrive soon enough to ease the pressure in the near term.